MLMolly Siu Ching Li

Molly Siu Ching Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Molly Siu Ching Li has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Landon L. Chan

    State Key laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

    6 shared publications
  • Olivia H. Chen

    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China

    6 shared publications
  • Tony S.K. Mok

    State Key laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

    6 shared publications
  • Kevin K.S. Mok

    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China

    5 shared publications
  • Wesley K.Y. Wong

    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China

    5 shared publications
  • Allen C.C. Chen

    Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China

    3 shared publications

Latest Publications

  • Open Access

    Prognostic Factors of Chinese Non-Small Cell Lung Cancer Patients with Best Supportive Care

    by Joyce May Sum Leung, Molly Siu Ching Li, Kwok Sing Ng

    Background/Objectives: To identify the potential prognostic factors of overall survival in Chinese patients with non-small cell lung cancer (NSCLC) who opted for best supportive care (BSC) alone. Methods: This retrospective study investigated the patients with newly diagnosed NSCLC who underwent staging FDG PET/CT at Queen Elizabeth Hospital between 1st Jan 2018 and 31st Mar 2024, then managed with BSC exclusively without surgery, radiotherapy or systemic therapy. The subjects had regular follow-up from oncologists and/or palliative medicine physicians until death. Potential prognostic determinants of overall survival were evaluated, including age, gender, performance status, co-morbidities, smoking history, previous malignancy, lung tumor histology, serum tumor marker (carcinoembryonic antigen), maximum tumor diameter as well as maximum Standardized Uptake Value (SUVmax) of the primary tumor, number of metastatic organs, and the presence of pleural or pericardial effusion. For statistical evaluation, univariate log-rank tests and multivariate Cox proportional hazards regression were performed to identify independent prognostic factors. The rationale for BSC and the eventual causes of death were also analyzed. Results: Univariate analysis identified male gender, poorer performance status, histology of NSCLC not otherwise specified, larger primary tumor, greater tumor SUVmax and the presence of pleural or pericardial effusion as negative prognostic factors. Subsequent multivariate Cox regression showed four factors retained independent statistical significance: gender, performance status, maximum tumor diameter and the presence of pleural/pericardial effusion. The three major rationales of the patients pursuing BSC were concerns regarding treatment side-effect (32.1%), advanced age (25.9%) and poor performance status (17.3%). The most common cause of death was pneumonia (76.7%). Conclusions: This study shows that gender, performance status, tumor diameter and presence of pleural/pericardial effusion are significant prognostic factors of overall survival in NSCLC patients receiving BSC exclusively.

  • Open Access

    An Interpretable Dynamic Host-Tumor Dual-Perspective Deep Learning Framework for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy in NSCLC

    by Jiaqi Zhou, Jianfeng Zhang, Xiuzhen Li, Xue Yang, Xiang Yan, Xiaolong Ma, Jie Zhao, Lan Yu, Long Bai, Liang Zeng, et al.

    Background: Pathological response following neoadjuvant chemoimmunotherapy is a robust prognostic predictor for non-small cell lung cancer (NSCLC), however, which remains impossible for preoperative non-invasive assessment. Since radiographic response often diverges from pathological regression, we aimed to develop an interpretable dynamic multimodal deep-learning framework that integrates longitudinal tumor imaging with host immuno-metabolic (IM) surrogates to predict pathological response after neoadjuvant chemoimmunotherapy. Methods: 901 patients with stage II-IIIB NSCLC undergoing surgical resection following neoadjuvant immunochemotherapy were collected from five institutions, consisting of a training (n=686), a validation (n=120), and two test cohorts (n=70 and 25). Deep HostTumor Dynamic (DeepHTD) platform combines a tumor-evolutionary (TE) module derived from serial CT imaging with an IM module incorporating fully automated body-composition features, laboratory variables, and clinical characteristics. The model provides real-time prediction of major pathological response. Findings: Thirteen immuno-metabolic patterns and 128-dimensional image features were eventually employed to establish DeepHTD. The platform demonstrated robust predictive performance across all cohorts, with AUCs of 0·851 in the training, 0·847 in validation, 0·876 and 0·849 in two test cohorts. Removing either IM or TE module consistently impaired predictive performance, supporting the complementary value of host-side and tumor-side dynamics. DeepHTD also outperformed static baseline or preoperative tumor imaging models. Model predicted response groups were significantly associated with EFS in the training, validation, and test cohorts. Decision curve analysis further suggested potential clinical utility for guiding surgery versus continued-therapy decisions after neoadjuvant treatment. Interpretation: We developed an interpretable platform integrating longitudinal tumor imaging and host immuno-metabolic surrogates, enabling dynamic prediction of MPR after before surgery. This multimodal deep-learning approach may inform personalized neoadjuvant strategies and surgical timing, pending prospective validation.

  • Open Access

    Optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a systematic review and meta-analysis

    by Zelong Chen, Molly S. C. Li, W. K. Jacky Lam

    Background: The optimal duration of adjuvant immunotherapy following neoadjuvant chemoimmunotherapy and surgery for resectable non-small cell lung cancer (NSCLC) remains unclear. This systematic review and meta-analysis aimed to compare the efficacy of 12/13-cycle versus 6/8-cycle adjuvant programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor therapy in this clinical setting. Methods: A systematic search of PubMed, Embase, the Cochrane Library, and major oncology conferences was performed from database inception to July 31, 2024. Eligible studies were phase II/III randomized controlled trials evaluating perioperative PD-1/PD-L1 inhibitor plus neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone. Hazard ratios (HRs) for survival outcomes were synthesized using the inverse-variance method. Indirect comparisons between the 12/13-cycle and 6/8-cycle adjuvant immunotherapy were performed using frequentist methods, with chemotherapy as a common comparator. The primary outcome was event-free survival (EFS). Results: Four trials involving 12/13-cycle adjuvant immunotherapy and two trials with 6/8-cycle regimens, totaling 3,003 patients, were included. Direct meta-analysis demonstrated significant improvements in EFS for chemoimmunotherapy compared with chemotherapy alone in both 12/13-cycle and 6/8-cycle adjuvant groups. In the indirect comparison, 12/13 cycles of adjuvant immunotherapy did not significantly improve EFS (HR, 1.05; 95% confidence interval: 0.77–1.45) compared with the 6/8-cycle regimen. However, a trend favoring 12/13 cycles of adjuvant therapy was observed in the PD-L1 expression ≥50% subgroup (P for interaction =0.02). Conclusions: Adjuvant immunotherapy with 6–8 cycles may be sufficient for patients with resectable NSCLC who have already received neoadjuvant chemoimmunotherapy. Further clinical trials are needed to determine the optimal duration of adjuvant therapy, particularly for patients with PD-L1 ≥50%.


  • Dual PD-1 and VEGF blockade in oncogene-negative NSCLC: where do we stand?

    by Jeng-Sen Tseng, Stephanie Pl Saw, Molly Sc Li

  • Top Cited Papers

    Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches

    by Jing Zhao, Wanting Xu, Fei Zhou, Xiangyu Zhang, Mo Zhou, Da Miao, Lan Yu, Yongchang Zhang, Junqiang Fan, Caicun Zhou, et al.

    Resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major obstacle in the clinical management of EGFR-mutant non-small-cell lung cancer (NSCLC). Despite the transformative therapeutic activity of the multiple iterations of EGFR TKIs, spanning from first-generation reversible inhibitors such as erlotinib and gefitinib to the current standard-of-care third-generation covalent inhibitor osimertinib, primary or acquired resistance to these agents inevitably emerges via diverse mechanisms. The advent of combination therapies that incorporate chemotherapy, anti-angiogenic agents, bispecific antibodies or antibody–drug conjugates has increased clinical benefit but introduced new resistance phenotypes, underscoring the dynamic plasticity and complexity of tumour evolution under therapeutic pressure. In this Review, we provide a comprehensive synthesis of the molecular mechanisms that underlie resistance to third-generation EGFR TKIs, describe biomarker-guided and biomarker-unselected therapeutic strategies to overcome these mechanisms, and discuss emerging approaches to pre-empt resistance through early application of combination therapies. We highlight the paradigm shift from radiological to molecular monitoring of resistance to therapy and explore how advances in circulating tumour DNA analysis, artificial intelligence and multi-omics might facilitate adaptive treatment strategies. As the therapeutic landscape evolves, a more complete mechanistic understanding of resistance will be essential to guide rational treatment sequencing, inform trial design and improve long-term outcomes for patients with EGFR-mutant NSCLC.


  • Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib

    by Allen C.C. Chen, Florence S.T. Mok, Wesley K.Y. Wong, Benjamin H.W. Lam, David Johnson, Matthew M.P. Lee, Landon L. Chan, Frankie Mo, Kevin K.S. Mok, Olivia H. Chen, et al.


  • CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression

    by Wesley K.Y. Wong, Kevin K.S. Mok, Giselle P.C. Tsui, Olivia H. Chen, Herbert H.F. Loong, Landon L. Chan, Kelvin Yan, Frankie Mo, Kirsty W.C. Lee, K.C. Lam, et al.


  • Open Access

    Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer

    by Stephanie P.L. Saw, Wen-Zhao Zhong, Rui Fu, Molly S.C. Li, Yasushi Goto, Stephen B. Fox, Yasushi Yatabe, Boon-Hean Ong, Calvin S.H. Ng, David D.W. Lee, et al.